Literature DB >> 27446386

Low-frequency ultrasound-mediated microvessel disruption combined with docetaxel to treat prostate carcinoma xenografts in nude mice: A novel type of chemoembolization.

Yu Yang1, Wenkun Bai1, Yini Chen1, Shuliang Nan1, Yanduan Lin1, Tao Ying1, Bing Hu1.   

Abstract

The aim of the present study was to investigate whether low-frequency ultrasound (US)-mediated microvessel disruption combined with docetaxel (DTX) can be used as a novel type of chemoembolization. Mice were assigned to four groups: i) The USMB group, treated with low-frequency US combined with microbubbles (USMB); ii) the DTX group, treated with DTX; iii) the USMB + DTX group, treated with combined therapy; and iv) the control group, which was untreated. Immediately after the first treatment, the average peak intensity (API) on contrast-enhanced US was calculated, and tumors were excised for hematoxylin and eosin (HE) staining. At 2 weeks post-treatment, the tumor volumes and wet weights were calculated, and tumors were excised for immunohistochemistry to calculate apoptotic index (AI), proliferative index (PI) and microvessel density (MVD) values. Immediately after the first treatment, in the DTX and control groups, the tumors demonstrated abundant perfusion enhancement, while in the USMB + DTX and USMB groups, blood perfusion of the tumors was interrupted. Compared with that of the control group, the API was significantly lower in the USMB + DTX USMB groups (all P<0.001). HE staining showed that tumor microvasculature was disrupted into flaky hematomas and severely dilated microvessels in the USMB + DTX and USMB groups. In the DTX and control groups, there was no distinct evidence of the disruption and dilation of blood microvessels. At the end of the treatment, the mean tumor inhibition ratio was 73.33, 46.67 and 33.33% for the USMB + DTX, DTX and USMB groups, respectively. The USMB + DTX group had the highest AI, and the lowest PI and MVD compared with the other groups, although the difference between the USMB + DTX and DTX groups with regard to PI and MVD was not significant (USMB + DTX vs. DTX group, P=0.345 and P=0.059, respectively). In conclusion, as a novel type of chemoembolization, USMB combined with DTX is more effective than USMB or DTX alone in inhibiting tumor growth via the enhancement of apoptosis, and the suppression of proliferation and angiogenesis.

Entities:  

Keywords:  docetaxel; low-frequency ultrasound; microbubble; prostate carcinoma; tumor vasculature

Year:  2016        PMID: 27446386      PMCID: PMC4950530          DOI: 10.3892/ol.2016.4703

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  36 in total

1.  Optimization of low-frequency low-intensity ultrasound-mediated microvessel disruption on prostate cancer xenografts in nude mice using an orthogonal experimental design.

Authors:  Y U Yang; Wenkun Bai; Yini Chen; Yanduan Lin; Bing Hu
Journal:  Oncol Lett       Date:  2015-09-17       Impact factor: 2.967

2.  Vascular effects induced by combined 1-MHz ultrasound and microbubble contrast agent treatments in vivo.

Authors:  Joo Ha Hwang; Andrew A Brayman; Michael A Reidy; Thomas J Matula; Michael B Kimmey; Lawrence A Crum
Journal:  Ultrasound Med Biol       Date:  2005-04       Impact factor: 2.998

3.  Blood vessel deformations on microsecond time scales by ultrasonic cavitation.

Authors:  Hong Chen; Wayne Kreider; Andrew A Brayman; Michael R Bailey; Thomas J Matula
Journal:  Phys Rev Lett       Date:  2011-01-18       Impact factor: 9.161

4.  Shock-induced collapse of a bubble inside a deformable vessel.

Authors:  Vedran Coralic; Tim Colonius
Journal:  Eur J Mech B Fluids       Date:  2013-07       Impact factor: 2.183

5.  The antiangiogenic property of docetaxel is synergistic with a recombinant humanized monoclonal antibody against vascular endothelial growth factor or 2-methoxyestradiol but antagonized by endothelial growth factors.

Authors:  C J Sweeney; K D Miller; S E Sissons; S Nozaki; D K Heilman; J Shen; G W Sledge
Journal:  Cancer Res       Date:  2001-04-15       Impact factor: 12.701

Review 6.  Acoustic behavior of microbubbles and implications for drug delivery.

Authors:  Klazina Kooiman; Hendrik J Vos; Michel Versluis; Nico de Jong
Journal:  Adv Drug Deliv Rev       Date:  2014-03-23       Impact factor: 15.470

7.  Blood vessel rupture by cavitation.

Authors:  Hong Chen; Andrew A Brayman; Michael R Bailey; Thomas J Matula
Journal:  Urol Res       Date:  2010-08-02

8.  Inhibitory effects of subcutaneous tumors in nude mice mediated by low-frequency ultrasound and microbubbles.

Authors:  Zhi-Yong Shen; E Shen; Xue-Hong Diao; Wen-Kun Bai; Min-Xia Zeng; Yan Yan Luan; Shu-Liang Nan; Yan-Duan Lin; Cong Wei; Li Chen; DI Sun; Bing Hu
Journal:  Oncol Lett       Date:  2014-03-04       Impact factor: 2.967

9.  Ultrasound-enhanced ocular delivery of dexamethasone sodium phosphate: an in vivo study.

Authors:  Marjan Nabili; Aditi Shenoy; Shawn Chawla; Sankaranarayana Mahesh; Ji Liu; Craig Geist; Vesna Zderic
Journal:  J Ther Ultrasound       Date:  2014-03-31

10.  Ultrasound-mediated gene and drug delivery using a microbubble-liposome particle system.

Authors:  Young Il Yoon; Yong-Su Kwon; Hee-Sang Cho; Sun-Hee Heo; Kyeong Soon Park; Sang Gyu Park; Soo-Hong Lee; Seung Il Hwang; Young Il Kim; Hwan Jun Jae; Gook-Jun Ahn; Young-Seok Cho; Hakho Lee; Hak Jong Lee; Tae-Jong Yoon
Journal:  Theranostics       Date:  2014-09-05       Impact factor: 11.556

View more
  2 in total

1.  Ultrasound Therapy, Chemotherapy and Their Combination for Prostate Cancer.

Authors:  William Lopez; Nhu Nguyen; Jessica Cao; Christine Eddow; K Kirk Shung; Nan Sook Lee; Mosses S S Chow
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

2.  UTMD-Promoted Co-Delivery of Gemcitabine and miR-21 Inhibitor by Dendrimer-Entrapped Gold Nanoparticles for Pancreatic Cancer Therapy.

Authors:  Lizhou Lin; Yu Fan; Feng Gao; Lifang Jin; Dan Li; Wenjie Sun; Fan Li; Peng Qin; Qiusheng Shi; Xiangyang Shi; Lianfang Du
Journal:  Theranostics       Date:  2018-02-14       Impact factor: 11.556

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.